As a leader in neuroendocrine neoplasm (NEN) research, our team is dedicated to improving patient outcomes with cutting-edge therapies. Under the guidance of Professor Ming Lu, Chief Physician at Peking University Cancer Hospital and Beijing GoBroad Hospital, we explore the latest advancements in NEN treatment, particularly as we look towards 2025.

Current Status of Neuroendocrine Neoplasm Treatment

Neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) present unique challenges in treatment. For gastroenteropancreatic NETs, we have a variety of options, including octreotide and lanreotide, as well as advanced therapies like peptide receptor radionuclide therapy (PRRT). Unfortunately, treatment options for pulmonary NETs remain limited. For NECs, the situation is even more challenging, with standard recommendations focusing on platinum-based combination chemotherapy, such as etoposide with cisplatin.

At GoBroad, we recognize the critical need for more effective treatments in NENs, which have historically been overlooked compared to more prevalent cancers like lung and colorectal cancer. Through our research and clinical trials, we aim to change this narrative.

Advances in Novel Therapies for NENs

The landscape of cancer treatment is rapidly evolving, and immunotherapy has emerged as a cornerstone for many cancer types. However, its application in NENs is complex due to the inherent heterogeneity of these tumors. While monotherapy with immune checkpoint inhibitors has shown limited efficacy, certain subgroups, particularly well-differentiated pancreatic NETs, may benefit from targeted approaches. Our efforts include developing new PD-L1 immunohistochemical testing kits to better identify potential responders.

Additionally, targeted therapy options are gaining traction. For instance, LBL-024, a bispecific antibody that targets PD-L1 and enhances the immune response, has shown promising results in clinical trials. With an objective response rate of 33.3% for non-pulmonary NECs, LBL-024 is a breakthrough in cell targeted therapy, demonstrating significant advantages over existing treatments.

Future Directions in Cell Targeted Therapy

As we look to the future, DLL3-targeted therapies are at the forefront of our research. Agents like Tarlatamab and HPN 328 have shown remarkable efficacy in early trials, particularly for small-cell lung cancer and other NENs. These therapies are designed to engage T-cells directly with the tumor, enhancing the immune response where it is needed most.

At GoBroad, we believe that ongoing research and clinical trials are essential for unlocking the full potential of cell targeted therapy. Our commitment to innovation, combined with expert insight from leading clinicians, positions us to make significant strides in the treatment of NENs.

Conclusion

In conclusion, cell targeted therapy represents a beacon of hope for patients with neuroendocrine neoplasms. At GoBroad, we are dedicated to pioneering advancements in this field, guided by expert insight and a commitment to research. As we approach 2025, we are excited about the future of NEN treatment and the potential to improve patient outcomes through targeted therapies. Together, we are transforming the landscape of cancer care, one breakthrough at a time.